Drugs / Dermatophagoides farinae
Dermatophagoides farinae
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05525650 | Jan 2022 → Dec 2024 | allergic rhinitis | RAPHAS | Unknown | No outcome recorded |
| Phase 1 | NCT03023397 | Mar 2017 → Apr 2018 | — | University of North Carolina, Chapel Hill | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT05395689 | Jan 2022 → Jun 2026 overdue | house allergic alveolitis | Probelte Pharma S.L.U. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dermatophagoides farinae | “The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of Dermatophagoides farinae (Der f), or house dust mite,...” NCT03023397 ↗ |
| Known as | Der f | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03023397 ↗ |
| Known as | House Dust Mite Extract, Dermatophagoides Farinae | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05525650 ↗ |
| Known as | House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05395689 ↗ |
| Modality | Vaccine | “The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year” NCT05395689 ↗ |
| Route | Intranasal | “Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU” NCT03023397 ↗ |